Amit Chunilal Nathwani
Founder at Freeline Therapeutics Ltd.
Amit Chunilal Nathwani active positions
| Companies | Position | Start | End |
|---|---|---|---|
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | 2014-12-31 | - |
| Chief Tech/Sci/R&D Officer | 2014-12-31 | - | |
| Founder | 2014-12-31 | - | |
| University College London | Corporate Officer/Principal | 2011-10-31 | - |
| Royal Free Hospital Medical School | Corporate Officer/Principal | 2012-10-31 | - |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Director/Board Member | - | - |
| Chief Executive Officer | - | - | |
| Founder | 2018-12-31 | - |
Career history of Amit Chunilal Nathwani
Former positions of Amit Chunilal Nathwani
| Companies | Position | Start | End |
|---|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Director/Board Member | 2020-06-25 | 2023-04-03 |
| Chief Tech/Sci/R&D Officer | 2021-08-19 | 2022-02-28 | |
| Founder | 2014-12-31 | 2023-04-03 | |
| Independent Dir/Board Member | 2020-04-02 | 2023-04-03 |
Training of Amit Chunilal Nathwani
| The Open University | Doctorate Degree |
| University of Aberdeen | Undergraduate Degree |
Statistics
International
| United Kingdom | 8 |
Operational
| Director/Board Member | 3 |
| Founder | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
Sectoral
| Consumer Services | 5 |
| Health Technology | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |